Melanoma is curable when caught early, and even advanced cases now have treatment options that can produce long-lasting remissions. Localized melanoma, the kind that hasn’t spread beyond the original skin site, has a 5-year survival rate of 100%. Once it reaches nearby lymph nodes, that drops to 76%, and melanoma that has spread to distant organs has a 34% survival rate. The stage at diagnosis determines everything about how melanoma is treated and how likely it is to be eliminated.
What “Cured” Means for Melanoma
Doctors rarely use the word “cured” with any cancer, including melanoma. Instead, they use terms like “no evidence of disease” (NED) or “complete remission,” both meaning no cancer is currently detectable on scans, bloodwork, or biopsies. There is no specific number of years you need to go without a recurrence to earn a different label. A person five years out hears the same terminology as someone one year out.
That said, the practical reality is that early-stage melanoma removed with surgery has an extremely high chance of never coming back. For many people with thin, localized tumors, surgery alone is the only treatment they’ll ever need, and their long-term outlook is essentially the same as someone who never had melanoma.
Surgery: The Primary Treatment
For most melanoma, surgery is the first and most important step. The initial biopsy confirms the diagnosis, but a second, wider surgery called a wide local excision removes a margin of healthy skin around the tumor site to make sure no cancer cells remain. How much skin is removed depends on how deep the melanoma grew into the skin, measured in millimeters.
- Melanoma in situ (confined to the top layer of skin): 0.5 cm margin
- Less than 1.0 mm deep: 1 cm margin
- 1.0 to 2.0 mm deep: 1 or 2 cm margin
- More than 2.0 mm deep: 2 cm margin
For melanomas thicker than 0.8 mm, or thinner ones that show ulceration (a break in the skin over the tumor), doctors typically recommend a sentinel lymph node biopsy. This procedure identifies the first lymph node that drains from the tumor site and checks whether cancer cells have traveled there. A positive result changes the stage and opens up additional treatment options. For tumors between 1.0 and 4.0 mm thick, sentinel lymph node biopsy is a standard recommendation.
Immunotherapy for Higher-Risk Melanoma
Immunotherapy has transformed melanoma treatment over the past decade. These drugs work by releasing the brakes on your immune system so it can recognize and attack cancer cells it was previously ignoring. Checkpoint inhibitors targeting a protein called PD-1 are the backbone of modern melanoma treatment, used both after surgery to reduce recurrence risk and as a primary weapon against advanced disease.
Among patients with advanced melanoma who achieve a complete response (meaning their tumors disappear entirely on scans), melanoma-specific survival reaches 96%. More than half of those complete responders live at least a year with no sign of the cancer returning, and some responses have lasted several years and counting.
Before or After Surgery
For patients with bulky or high-risk melanoma (stage IIIC or IV that can still be surgically removed), there’s growing evidence that receiving immunotherapy both before and after surgery produces better results than surgery followed by immunotherapy alone. In a clinical trial comparing these two approaches, the group that received immunotherapy before surgery had a 2-year event-free survival of 72%, compared to 49% for those who only received it afterward. Starting immunotherapy while the tumor is still in the body appears to give the immune system a stronger target to learn from, producing a more durable response.
Targeted Therapy for BRAF-Mutant Melanoma
About half of all melanomas carry a specific gene mutation called BRAF. If your tumor tests positive for this mutation, you may be eligible for targeted therapy: drugs that block the specific proteins driving your cancer’s growth. These are typically given as a combination of two oral medications, one targeting BRAF and one targeting a related pathway called MEK.
The combination approach works significantly better than either drug alone. In clinical trials, the paired treatment produced tumor shrinkage in 68% of patients, compared to 51% for the BRAF-targeting drug by itself. Targeted therapy tends to work quickly, often shrinking tumors within weeks, which makes it particularly useful when rapid tumor reduction is needed. However, resistance can develop over time, which is why immunotherapy is often preferred as a first-line treatment when the situation allows for it.
TIL Therapy: A Newer Option for Tough Cases
For patients whose melanoma has progressed despite immunotherapy and targeted therapy, a newer treatment called TIL (tumor-infiltrating lymphocyte) therapy became available in 2024. This is the first cell-based therapy approved for a solid tumor cancer. The process involves surgically removing a piece of your tumor, extracting the immune cells found inside it, growing billions of those cells in a lab, and then infusing them back into your body.
Among patients treated with TIL therapy after other treatments had failed, nearly one-third saw their tumors shrink, with some achieving complete disappearance of detectable cancer. About 10% of those responses are still ongoing years later. The treatment is intensive: it requires healthy heart and lung function because patients receive high-dose chemotherapy before the infusion and a potent immune-stimulating drug afterward. This limits who can safely undergo it, but for eligible patients who have run out of standard options, TIL therapy represents a meaningful chance at durable remission.
What Determines Your Outlook
The single biggest factor in melanoma outcomes is how early it’s found. Melanoma confined to the skin is treated with surgery alone in many cases and carries that 100% 5-year survival rate. Once it reaches lymph nodes, the picture changes, but modern immunotherapy has dramatically improved outcomes even at this stage. Distant metastatic melanoma remains the most challenging, though the 34% 5-year survival rate is a significant improvement over what was possible before immunotherapy became available, when that number was in the single digits.
Other factors that influence prognosis include tumor thickness, whether the surface is ulcerated, how quickly the cancer cells are dividing, and whether the tumor carries treatable mutations like BRAF. Your treatment team considers all of these when building a plan. For early-stage disease, that plan may be straightforward surgery. For advanced disease, it often involves a carefully sequenced combination of surgery, immunotherapy, and possibly targeted therapy, with each step informed by how the cancer responds.
After treatment, regular skin checks and imaging (for higher-risk patients) continue for years. Melanoma can recur late, sometimes a decade or more after the original diagnosis, so ongoing monitoring matters even when things look clear.